The Female Health Company/Partners Launch Three New Webinars, Newsletter

CHICAGO, March 31, 2016 -- The Female Health Company (NASDAQ:FHCO) (FHC or the Company) today announced the rollout of three large scale webinars by the FHC Education Team. 

Developed to educate U.S. healthcare providers on reimbursability via the Affordable Care Act (ACA), the first webinar and accompanying materials were created with assistance from FHC’s partners the National Coalition of STD Directors (NCSD) and the National Family Planning and Reproductive Health Association (NFPRHA).  These resources provide information and education to help women in the U.S. gain more affordable access to FC2 through ACA and/or Medicaid.

A separate webinar was held in partnership with The Southeast AIDS Education and Training Center (SEAETC) to provide FC2 refresher facts and updates.  FHC also offered a comprehensive webinar update on FC2, with a focus on FC2 in the prevention of Zika, to the Regional Resource Network Program at the U.S. Department of Health and Human Services’ (HHS) ten regional offices.

On March 21, 2016, the first issue of the FHC U.S. Public Health Newsletter was distributed to more than 3,000 public health professionals.  The newsletter will be issued bi-monthly and will alternate with a U.S. retail/commercial sector newsletter, launching in April 2016.

About The Female Health Company

The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom^® (FC2). Since the Company began distributing FC2 in 2007, the product has been shipped to 144 countries. The Company owns certain worldwide rights to the FC2 Female Condom^®, including patents that have been issued in a number of countries around the world. The patents cover key aspects of FC2, including its overall design and manufacturing process.  The FC2 Female Condom^® is the only currently available female-controlled product approved by FDA that offers dual protection against sexually transmitted infections, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.

For more information about the Female Health Company visit the Company's website at http://www.femalehealth.com and http://www.femalecondom.org. If you would like to be added to the Company's e-mail alert list, please send an e-mail to [email protected].

Contacts:
William R. Gargiulo, Jr. 231.526.1244
Michele Greco, CFO 312.595.9123